📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-28 11:22
136 analysed today
FollowTelegram
136
Today
149,537
All-time analysed
42,893
Positive
6,653
Negative
91,318
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
QMS Medical signs MoU to acquire 100% of deep-tech firm BeamOptics Scientific
QMS Medical Allied Services has signed an MoU to acquire a 100% equity stake in BeamOptics Scientific Private Limited, a Pune-based deep-tech IVD and analytical instruments manufacturer founded in 2023. The transaction value and financial terms were not disclosed. The finalization is contingent on NCLT approval of QMS's composite scheme of arrangement involving the demerger of its services arm into Saarathi Healthcare and its merger with HCAH. This acquisition aims to reinforce QMS's core product business following the corporate restructuring.
Confidence: MEDIUM
What changedQMS has signed a non-binding/initial MoU to acquire 100% ownership of Pune-based diagnostic device maker BeamOptics Scientific.
Why it mattersAdds proprietary deep-tech manufacturing and IP in IVD instruments to bolster QMS's retained product segment after its service operations are demerged.
Equity stake to acquire: 100%Acquisition cost/valuation: not disclosedTarget founding year: 2023HEINE agreement tenure: 5 years
📅 Short termMarket sentiment will be influenced by the deep-tech IP narrative, but immediate financial impact is muted until deal consideration and definitive terms are disclosed.
📈 Long termIf successfully integrated post-NCLT demerger, BeamOptics provides proprietary hardware IP to support product division margins, which traditionally operate at lower margins (10-12%) than the services arm.
⚠ Risk flags
- Deal terms and acquisition valuation not disclosed
- Execution contingent on pending NCLT approvals for composite restructuring
- Early-stage target company (founded 2023) with unproven commercial scale
Key Highlights
Signed MoU to acquire 100% equity shares of Pune-based BeamOptics Scientific Private Limited
BeamOptics was founded in 2023 and holds proprietary patents in FTIR spectroscopy platforms
Acquisition completion is subject to NCLT approval of a composite scheme of arrangement with HCAH
Strategic restructuring underway to demerge services business into Saarathi Healthcare and list it separately
Complements an exclusive 5-year India distribution pact signed in August 2026 with Germany's HEINE Optotechnik
👀 What to Watch
Track disclosures regarding the definitive agreement, acquisition cost, funding mode (cash vs dilution), and progress on NCLT approvals for the Saarathi-HCAH scheme.
QMS and HCAH Sign Definitive Deal to Merge PSP Businesses into Saarathi Healthcare
QMS Medical Allied Services and Health Care At Home India (HCAH) have signed definitive documents to merge their pharma services businesses into Saarathi Healthcare, a 100% subsidiary of QMS. The combined platform will operate over 160 Patient Support Programs (PSPs) reaching more than 1.2 million patients with a workforce of 2,000+ professionals across 35+ cities. The strategic combination positions QMS to capitalize on India's PSP market, which is projected to reach approximately US$1 billion by 2030, growing at 15-20% CAGR.
Confidence: HIGH
What changedQMS and HCAH have entered a definitive agreement to consolidate their pharma services and PSP operations under QMS's subsidiary, Saarathi Healthcare.
Why it mattersThe deal significantly enhances QMS's high-margin services segment (which commands 20-22% margins compared to 10-12% in products) by creating India's largest patient support program platform.
Patient Support Programs: 160+Patients impacted: 1.2 million+Team strength: 2,000+ professionalsGeographical footprint: 35+ citiesTarget India market by 2030: c.US$1 billion
📅 Short termPositive sentiment is expected following definitive documentation with an established institutional player (backed by Burmans and Quadria Capital), though transaction valuation details remain undisclosed.
📈 Long termPositions Saarathi as a dominant national player in PSPs, directly feeding QMS's strategy to scale higher-margin service revenues and improve overall ROCE.
⚠ Risk flags
- Financial terms, valuation, and post-merger shareholding structure of Saarathi were not disclosed in the press release
- Integration risks spanning 2,000+ personnel across 35+ cities
Key Highlights
Definitive agreement signed to merge PSP businesses of HCAH and QMS into Saarathi Healthcare, a 100% subsidiary of QMS
Combined platform will operate 160+ Patient Support Programs impacting over 1.2 million+ patients
Deployment of 2,000+ professionals across 35+ cities serving top Indian and MNC pharma clients
Addresses an Indian PSP market expanding at 15-20% CAGR to reach ~US$1 billion by 2030 (global market at ~US$70 billion)
👀 What to Watch
Track subsequent regulatory disclosures for final share-swap or equity structure details in Saarathi Healthcare, along with revenue contribution in upcoming quarterly reports.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
QMS Medical Approves Demerger of Services Arm into Saarathi Healthcare (1:1 Share Swap)
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, ~24.41% of FY26 turnover) into Saarathi Healthcare. In addition, the healthcare services division of Health Care at Home India (HCAH) is also being merged into Saarathi, creating a combined healthcare services entity to be listed separately. Under the scheme, QMS shareholders will receive 1 share of Saarathi Healthcare (face value Rs 10) for every 1 share held in QMS. Concurrently, QMS entered into an MoU to acquire 100% of BeamOptics Scientific Pvt Ltd (FY26 revenue Rs 1.14 Cr) by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its Healthcare Services Business and combining it with HCAH's service business under Saarathi Healthcare, which will be separately listed.
Why it mattersSeparates the high-margin healthcare services division into a dedicated listed entity, unlocking direct shareholder value via a 1:1 share distribution while maintaining QMS's core medical products business.
Demerged division FY26 turnover: Rs. 37.17 CroresDemerged share of FY26 turnover: 24.41%Share swap ratio (QMS to Saarathi): 1:1Saarathi post-arrangement total shares: 3,25,00,066BeamOptics FY26 turnover: Rs. 113.81 Lakhs
📅 Short termMarket may view the planned separate listing and 1:1 mirror share distribution positively, though stock exchange and NCLT approval timelines are lengthy.
📈 Long termConsolidates Saarathi and HCAH service businesses to create a scaled patient-support service provider, giving shareholders direct equity in two distinct corporate vehicles.
⚠ Risk flags
- Subject to approvals from NCLT, NSE, shareholders, and creditors
- Indicative completion timeline spans well into 2027
- Valuation and cash/equity consideration for BeamOptics acquisition yet to be finalized
Key Highlights
Demerged division contributed Rs 37.17 Cr, or 24.41% of QMS turnover in FY26
Share swap ratio set at 1 equity share of Saarathi Healthcare for every 1 share held in QMS
Post-arrangement Saarathi shareholding will be 40.5% Promoter and 59.5% Public (3.25 Cr total shares)
Proposed 100% acquisition of BeamOptics Scientific (FY26 revenue Rs 113.81 Lakhs) targeted by November 30, 2027
👀 What to Watch
Track the regulatory approvals process, including NCLT clearance, shareholder voting, and creditor consents for the scheme of arrangement.
QMS Medical approves demerger of services division & 100% buyout of BeamOptics
QMS Medical Allied Services has approved a Composite Scheme of Arrangement to demerge its Healthcare Services Business (revenue of Rs 37.17 Cr, or 24.41% of FY26 turnover) into Saarathi Healthcare Private Limited. Under the swap ratio, QMS shareholders will receive 1 equity share of Rs 10 each in Saarathi for every 1 share held in QMS. In parallel, QMS entered into an MOU to acquire 100% of BeamOptics Scientific Private Limited, which had FY26 turnover of Rs 113.81 Lakhs, with an expected completion timeline by November 30, 2027.
Confidence: HIGH
What changedQMS approved demerging its service arm into Saarathi Healthcare alongside a division of Health Care at Home India, while also agreeing to acquire BeamOptics Scientific.
Why it mattersThe demerger unlocks value by creating a dedicated listed healthcare services platform with separate management, while consolidating higher-margin PSP and healthcare service businesses.
Demerged division turnover (FY26): Rs. 37.17 CroresDemerged share of FY26 revenue: 24.41%Share exchange ratio (QMS to Saarathi): 1:1BeamOptics FY26 turnover: Rs. 113.81 LakhsDemerged business vs TTM revenue: ~20.3%
📅 Short termMarket is likely to view the corporate restructuring and separate listing of the high-margin service vertical positively, pending detailed scheme disclosures.
📈 Long termAllows QMS to sharpen its core operations while enabling Saarathi to operate as a focused healthcare services entity with distinct capital allocation and growth avenues.
⚠ Risk flags
- Execution timeline risk extending up to November 30, 2027 for acquisition completion
- Scheme is subject to approvals from NSE, SEBI, shareholders, creditors, and NCLT
Key Highlights
Demerged Healthcare Services business contributed Rs 37.17 Cr (24.41% of FY26 total turnover)
Share swap ratio of 1:1 for QMS shareholders into the resulting company (Saarathi Healthcare)
Post-arrangement Saarathi shareholding to consist of 40.5% promoters and 59.5% public (total 3,25,00,066 shares)
Agreed to acquire 100% of BeamOptics Scientific (FY26 turnover of Rs 113.81 Lakhs) on or before November 30, 2027
👀 What to Watch
Track the upcoming regulatory filings, shareholder and creditor approvals, and NCLT sanction timelines for the composite scheme of arrangement and the listing of Saarathi Healthcare.
QMS Medical Acquires Remaining 24% Stake in Saarathi Healthcare for ₹14.225 Cr
QMS Medical Allied Services has completed the 100% acquisition of Saarathi Healthcare Pvt Ltd, making it a wholly owned subsidiary. The company acquired the remaining 24% equity stake (1,98,000 shares) for a cash consideration of ₹14.225 crore, having previously held 76%. Saarathi operates in disease management, screening, and patient access programs, and its full integration supports QMS's broader target of surpassing ₹500 crore in revenue by FY29.
Confidence: HIGH
What changedQMS Medical raised its stake in Saarathi Healthcare from 76% to 100%, completing a full takeover.
Why it mattersFull ownership eliminates minority interest leakages and integrates Saarathi's higher-margin healthcare services (20-22% OPM) into QMS's core business.
Acquisition cost: ₹14.225 croreShares acquired: 1,98,000 sharesStake acquired: 24%Deal value vs Net Worth: ~13.7%Target FY29 Revenue: ₹500 crore
📅 Short termPositive sentiment from full integration, though investors will watch for cash flow impact given the ₹14.225 crore outlay against existing debt of ₹91 crore.
📈 Long termStrengthens QMS's higher-margin service vertical (Patient Support Programs and disease management), aiding its strategic expansion towards its ₹500 crore FY29 revenue goal.
⚠ Risk flags
- Cash outflow increases balance sheet leverage (Debt was ₹91 Cr vs Net Worth ₹104 Cr).
- Integration risks across digital platforms and operational teams.
Key Highlights
Acquired the remaining 24% equity stake (1,98,000 shares) for ₹14.225 crore in cash.
Saarathi Healthcare is now a 100% wholly owned subsidiary (up from 76% in Oct 2025 and 51% in Jun 2024).
Cash outflow of ₹14.225 crore represents approximately 13.7% of net worth (₹104 Cr) and 3.7% of market cap (₹383 Cr).
Management reaffirmed a long-term goal of surpassing ₹500 crore revenue by FY29.
👀 What to Watch
Track the upcoming Q3 FY27 consolidated earnings to monitor minority interest elimination and integration of Saarathi's higher-margin service revenues.
QMS Medical Acquires Remaining 24% Stake in Saarathi Healthcare for ₹14.23 Cr, Making it 100% WOS
QMS Medical Allied Services has acquired the remaining 24% equity stake in its subsidiary, Saarathi Healthcare Private Limited, for a cash consideration of ₹14.225 crore (1,98,000 shares). Following this transaction, Saarathi Healthcare becomes a wholly owned subsidiary (100% ownership). Saarathi reported a turnover of ₹18.45 crore in FY26, growing from ₹16.29 crore in FY25 and ₹13.33 crore in FY24. The acquisition cost represents approximately 13.7% of QMS Medical's net worth of ₹104 crore.
Confidence: HIGH
What changedQMS Medical increased its stake in Saarathi Healthcare from 76% to 100%, making it a wholly owned subsidiary.
Why it mattersSaarathi operates in higher-margin healthcare services (disease management and POC screening); 100% ownership allows full consolidation of earnings without profit leakage to minority shareholders.
Cost of acquisition: Rs. 14,22,50,000/-Acquisition cost vs Net worth: ~13.7%Stake acquired: 24%Saarathi FY26 Turnover: Rs. 1844.99/- (in Lakhs)Saarathi FY25 Turnover: Rs. 1629.47 Lakhs
📅 Short termPositive sentiment given full control over the strategic subsidiary, though cash outflow of ₹14.23 crore will impact short-term liquidity.
📈 Long termStrengthens position in value-added healthcare service programs with 20-22% margins, fully capturing subsidiary profits without non-controlling interests.
⚠ Risk flags
- Cash outflow of ₹14.23 crore relative to existing debt levels of ₹91 crore
- Operational performance of Saarathi Healthcare sustaining its historical growth rate
Key Highlights
Acquired 24% stake (1,98,000 shares) in Saarathi Healthcare Private Limited for ₹14,22,50,000 cash
Post-acquisition, equity shareholding increased from 76% to 100%, turning Saarathi into a wholly owned subsidiary
Saarathi Healthcare FY26 turnover stood at ₹1,844.99 lakh (₹18.45 crore), up from ₹1,629.47 lakh in FY25
Deal fully eliminates minority interest in the higher-margin healthcare services segment
👀 What to Watch
Track subsequent quarterly results for the elimination of non-controlling interest in consolidated earnings, and monitor service-segment margin contributions in upcoming FY27 releases.
QMS signs 5-year exclusive India distribution pact with HEINE; current India sales ~Rs 30 Cr
QMS Medical Allied Services has signed an exclusive five-year distribution agreement with German diagnostic instruments maker HEINE Optotechnik, effective January 1, 2027. Under the contract, QMS becomes the sole distributor for HEINE's diagnostic instruments in India. HEINE's net India revenue in CY2026 is expected to be around €2.6 million (~Rs 30 crore), representing ~16.4% of QMS's TTM revenue of Rs 183 crore. QMS targets scaling this turnover to Rs 70 crore by 2031.
Confidence: HIGH
What changedQMS secured exclusive India marketing and distribution rights for German diagnostic instrument manufacturer HEINE Optotechnik for five years starting January 2027.
Why it mattersProvides an immediate base of ~Rs 30 crore in annual distribution revenue (~16.4% of TTM revenue) with growth visibility to Rs 70 crore by 2031, bolstering QMS's medical devices division.
Agreement duration: 5 years (from 1st January 2027)HEINE 2026 India net revenue: 2.6 million Euros (~Rs. 30 crore)2026 India revenue vs TTM revenue: ~16.4%Targeted turnover by 2031: Rs. 70 crore
📅 Short termPositive sentiment from partnering with an established global OEM; direct financial impact will only start reflecting from Q4 FY27 when distribution commences.
📈 Long termStrengthens product portfolio scale and brand equity, aligning with company's broader target of reaching Rs 500 crore revenue by FY29.
⚠ Risk flags
- Product segment operates at lower margins (10-12%) compared to services (20-22%).
- Revenue realization delayed until distribution begins in January 2027.
- Execution and channel expansion risks to reach the targeted Rs 70 crore run-rate by 2031.
Key Highlights
5-year exclusive distribution agreement across India starting January 1, 2027.
HEINE's net India revenue for 2026 estimated at €2.6 million (~Rs 30 crore), or ~16.4% of QMS TTM revenue.
Projected partnership turnover targeted to increase to Rs 70 crore by 2031.
Includes full product exclusivity across ENT, dermatoscopes, ophthalmic, laryngoscopes, and spare parts.
👀 What to Watch
Track operational handover ahead of the January 1, 2027 launch date and observe product-segment revenue and margin contributions starting in Q4 FY27.
QMSMEDI Q1 FY27 Concall: Revenue up 22% YoY to ₹56.9 Cr, targeting 100% Saarathi buyout by Q2
QMS Medical Allied Services released its Q1 FY27 earnings call transcript following a 22% YoY revenue growth to ₹56.9 Cr and a 25% YoY PAT rise to ₹4.0 Cr. The Patient Support Program (PSP) segment, led by Saarathi Healthcare, contributed ~₹17 Cr in revenue during the quarter. The company currently holds 76% in Saarathi Healthcare and expects to complete the acquisition of the remaining 24% stake by Q2 FY27. Management continues to target an ~18% full-year EBITDA margin for FY27 versus 14.6% achieved in Q1.
Confidence: HIGH
What changedManagement conducted its Q1 FY27 post-results call, providing operational metrics on health camps, PSP revenue run-rate, and timelines for full consolidation of Saarathi Healthcare.
Why it mattersHigher-margin services (20-22% margin profile) and 100% ownership of Saarathi Healthcare will eliminate non-controlling interest deductions, supporting consolidated earnings growth.
Q1 FY27 Revenue: ₹56.9 CrQ1 FY27 EBITDA Margin: 14.6%Q1 FY27 PAT: ₹4.0 CrPSP/Saarathi Q1 Revenue: ₹17 CrHealth Camps in Q1: 11,497
📅 Short termPositive sentiment driven by sequential turnaround in profitability (PAT +110% QoQ) and migration to the NSE Main Board.
📈 Long termExpansion into tech-enabled PSPs and patented/specialty therapies combined with full integration of Saarathi provides steady structural growth in healthcare services.
⚠ Risk flags
- Seasonality in pharma marketing spends affecting quarterly camp volumes
- Execution risk in scaling EBITDA margin from current 14.6% to guided ~18%
Key Highlights
Q1 FY27 consolidated revenue grew 22% YoY to ₹56.9 Cr, with EBITDA up 27% YoY to ₹8.3 Cr.
PAT rose 25% YoY and 110% QoQ to ₹4.0 Cr with PAT margin improving to 7.0%.
PSP and services business generated ~₹17 Cr revenue; platform supports 100+ programs and over 1 million patients.
Conducted 11,497 B2B health camps during the quarter.
Management plans to acquire the remaining 24% stake in Saarathi Healthcare by end of Q2 FY27.
👀 What to Watch
Track the completion and funding of the remaining 24% acquisition in Saarathi Healthcare in Q2 FY27 and monitor if EBITDA margins expand toward the guided ~18% level in H2 FY27.
QMS Reports Q1FY27: Revenue Up 22% YoY to ₹56.9 Cr, PAT Up 25% to ₹4.0 Cr
QMS Medical Allied Services released its Q1FY27 investor presentation reporting consolidated revenue of ₹56.9 Cr, representing a 22% YoY growth. Consolidated EBITDA increased 27% YoY to ₹8.3 Cr with EBITDA margin expanding to 14.6%, while PAT rose 25% YoY to ₹4.0 Cr. The revenue mix shifted markedly toward higher-margin Services, which accounted for 41% of revenue compared to 24% in Q1FY26. The company completed 11,497 B2B health camps during the quarter and announced plans to acquire the remaining 24% stake in Saarathi Healthcare by the end of Q2FY27.
Confidence: HIGH
What changedPublished revised Q1FY27 investor presentation rectifying minor slide errors and detailing quarterly financial and operational progress.
Why it mattersDemonstrates rapid expansion in the higher-margin Patient Support Programs and Services segment, which commands 20-22% margins compared to 10-12% in product distribution.
Q1FY27 Consolidated Revenue: ₹56.9 CrYoY Revenue Growth: 22%Q1FY27 Consolidated EBITDA: ₹8.3 CrQ1FY27 Consolidated PAT: ₹4.0 CrServices Revenue Share: 41%B2B Health Camps Conducted: 11,497
📅 Short termProvides comprehensive quarterly operational data, reinforcing positive revenue and earnings momentum post migration to the NSE Main Board.
📈 Long termFull consolidation of Saarathi Healthcare and expanding digital health platforms provide a structural runway for higher-margin service revenues.
⚠ Risk flags
- Seasonality in pharma marketing spend cycles affecting quarterly camp volumes
- High leverage with debt of ₹91 Cr relative to net worth of ₹104 Cr (D/E of 0.88)
Key Highlights
Consolidated revenue grew 22% YoY to ₹56.9 Cr with PAT rising 25% YoY to ₹4.0 Cr in Q1FY27
Consolidated EBITDA increased 27% YoY to ₹8.3 Cr, with margins improving to 14.6% from 14.1%
Services share in total revenue expanded to 41% in Q1FY27 versus 24% in Q1FY26
Executed 11,497 B2B health camps during the quarter across India
Expects to acquire the balance 24% stake in subsidiary Saarathi Healthcare by end of Q2FY27
👀 What to Watch
Track the completion and closing terms of the remaining 24% acquisition in Saarathi Healthcare by Q2FY27 and monitor whether the Services mix continues to sustain higher consolidated margins.
QMS Medical Q1FY27: Revenue Up 22% YoY to ₹56.9 Cr; Services Share Expands to 41%
QMS Medical Allied Services reported a 22% YoY growth in consolidated Q1FY27 revenue to ₹56.9 crore, driven by a higher contribution from high-margin services. Consolidated EBITDA grew 27% YoY to ₹8.3 crore with an EBITDA margin of 14.6%, while PAT rose 25% YoY to ₹4.0 crore. The revenue mix shifted materially toward the Services segment, which now accounts for 41% of revenue versus 24% in Q1FY26. The company announced plans to acquire the remaining 24% stake in Saarathi Healthcare by the end of Q2FY27 to reach 100% ownership.
Confidence: HIGH
What changedQMS released its Q1FY27 investor presentation detailing strong operational performance and announcing a timeline (Q2FY27 end) to buy the remaining 24% stake in Saarathi Healthcare.
Why it mattersHigher-margin services (20-22% margin profile) are scaling rapidly relative to distribution products (10-12%), driving structural margin expansion and strengthening long-term pharma client stickiness.
Q1FY27 Net Revenue: ₹56.9 crQ1FY27 Revenue YoY growth: 22%Q1FY27 EBITDA: ₹8.3 crQ1FY27 PAT: ₹4.0 crServices Segment Mix: 41%B2B Health Camps Conducted: 11,497
📅 Short termSolid Q1 financial performance and steady growth momentum across patient support programs are positive triggers for market sentiment.
📈 Long termFull consolidation of Saarathi Healthcare and the shift toward digital health platforms and patient screening programs support durable margin improvement and organic growth.
⚠ Risk flags
- Quarterly seasonality tied to pharmaceutical clients' marketing budget cycles
- Integration and valuation terms for acquiring the remaining 24% stake in Saarathi Healthcare
- Dependency on global OEM distribution rights for device business
Key Highlights
Q1FY27 consolidated revenue rose 22% YoY to ₹56.9 crore (vs ₹46.5 crore in Q1FY26)
EBITDA increased 27% YoY to ₹8.3 crore with EBITDA margin expanding to 14.6% from 14.1%
Services segment contribution rose sharply to 41% of revenue in Q1FY27 from 24% in Q1FY26
Conducted 11,497 B2B health camps during the quarter
Expects to acquire the balance 24% stake in subsidiary Saarathi Healthcare by Q2FY27 end
👀 What to Watch
Track the completion and integration of the remaining 24% stake purchase in Saarathi Healthcare in Q2FY27 and monitor if higher-margin Services mix continues to lift consolidated operating margins.
QMSMEDI Q1 FY27 Results: Consolidated PAT Grows 25% YoY to ₹3.96 Cr on ₹56.87 Cr Revenue
QMS Medical Allied Services reported a strong start to FY27 with consolidated revenue growing 22.3% YoY to ₹56.87 Cr. Net profit for the quarter increased by 25.3% YoY to ₹3.96 Cr, showing a significant sequential recovery from the ₹1.88 Cr reported in Q4 FY26. The results reflect the company's typical seasonality where Q1 benefits from pharmaceutical companies exhausting marketing budgets. However, employee benefit expenses saw a sharp rise to ₹11.17 Cr from ₹0.22 Cr YoY, likely due to the consolidation of service-linked operations.
Confidence: HIGH
What changedThe company has reported its first-quarter results for FY27, demonstrating double-digit growth in both revenue and profit compared to the previous year.
Why it mattersThe results validate the company's growth strategy in the healthcare services segment, which offers higher margins (20-22%) compared to product trading. The sharp rise in employee costs suggests a structural shift towards a service-heavy model.
Consolidated Revenue (Q1 FY27): ₹56.87 CrConsolidated PAT (Q1 FY27): ₹3.96 CrRevenue Growth (YoY): 22.3%PAT Growth (YoY): 25.3%Q1 Revenue vs TTM Revenue: ~33%
📅 Short termThe strong YoY and sequential profit growth are likely to be viewed positively by the market in the short term, confirming the company's ability to scale.
📈 Long termThe long-term value depends on the successful transition from a medical device trader to a specialized healthcare service provider and the integration of Saarathi Healthcare.
⚠ Risk flags
- High seasonality (Q2 and Q3 are historically weaker)
- Significant spike in employee benefit expenses
- Dependency on pharmaceutical marketing budget cycles
Key Highlights
Consolidated Revenue from Operations increased 22.3% YoY to ₹56.87 Cr from ₹46.50 Cr.
Consolidated Net Profit rose 25.3% YoY to ₹3.96 Cr compared to ₹3.16 Cr in the same quarter last year.
Employee benefit expenses surged to ₹11.17 Cr, up from just ₹0.22 Cr in Q1 FY26, indicating a major shift in operational scale or consolidation.
Finance costs increased to ₹1.71 Cr from ₹1.44 Cr YoY, reflecting higher debt servicing or working capital needs.
Standalone revenue contributed ₹52.34 Cr, representing approximately 92% of the total consolidated turnover.
👀 What to Watch
Monitor the impact of the increased stake in Saarathi Healthcare (from 51% to 76%) on consolidated margins in the coming quarters. Investors should watch if the company can sustain its 25% growth target during the seasonally weaker Q2 and Q3 periods.
QMS Medical Migrates to NSE Mainboard; Targets Rs 500 Crore Revenue by FY2029
QMS Medical Allied Services has successfully migrated from the NSE Emerge platform to the NSE Mainboard as of June 18, 2026. The company reported a consolidated revenue of Rs 172.9 crore and an EBITDA of Rs 25.9 crore for FY26. Management has set an ambitious target to triple its revenue to Rs 500 crore by FY2029, shifting focus toward high-margin patient service programs. The migration is expected to enhance liquidity and attract institutional investors as the company scales its healthcare services vertical.
Key Highlights
Successfully migrated 1.93 crore equity shares to the NSE Mainboard effective June 18, 2026.
Reported FY26 consolidated revenue of Rs 172.9 crore and EBITDA of Rs 25.9 crore.
Targets 3x revenue growth to reach Rs 500 crore by FY2029.
Expects the services business to double in revenue by FY27 and contribute ~50% of total revenue by FY29.
Product business currently accounts for 69% of total revenues as of FY26.
👀 What to Watch
Investors should view the migration as a sign of maturing governance and operational scale, which may lead to institutional re-rating. Monitor the company's ability to meet its aggressive 3x revenue growth target and the margin expansion resulting from the higher-contribution services vertical.
QMS Medical Allied Services to Migrate to NSE Main Board on June 18, 2026
QMS Medical Allied Services Limited has received formal approval from the National Stock Exchange (NSE) to migrate its equity shares from the SME Emerge platform to the Main Board. A total of 19,337,443 equity shares with a face value of ₹10 each will be admitted for trading on the Capital Market Segment starting June 18, 2026. This transition typically leads to higher liquidity and increased visibility among institutional investors. Consequently, trading on the SME Emerge platform will be suspended effective from the same date.
Key Highlights
Migration of 19,337,443 equity shares from NSE Emerge to the NSE Main Board.
Trading on the Main Board is scheduled to commence on Thursday, June 18, 2026.
Trading on the SME Emerge platform will be suspended effective June 18, 2026.
The shares will trade under the symbol QMSMEDI in the 'EQ' series with a market lot of 1 share.
Approval received vide NSE letter Ref. No. NSE/LIST/298 dated June 16, 2026.
👀 What to Watch
Investors should monitor the stock for potential increases in trading volume and institutional participation as it moves to the Main Board. No action is required for existing shareholders as the migration is an automatic administrative transition for their holdings.
